THU092 Characterizing Immune Checkpoint Inhibitor Induced Hypophysitis In A Large Urban Health Care System

Disclosure: M. Gogerly-Moragoda: None. U. Sharif Khawaja: None. K.C. Cheesman: None. A. Leiter: None. E.J. Gallagher: Consulting Fee; Self; Novartis Pharmaceuticals, Flare Therapeutics, Seagen, SynDevRx. INTRODUCTION Over the past decade, immune checkpoint inhibitors (ICIs) have transformed cancer t...

Descripción completa

Detalles Bibliográficos
Autores principales: Gogerly-Moragoda, Mahalya, Khawaja, Umar Sharif, Cheesman, Khadeen C, Leiter, Amanda, Gallagher, Emily J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Neuroendocrinology & Pituitary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554541/
http://dx.doi.org/10.1210/jendso/bvad114.1172

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554541/
http://dx.doi.org/10.1210/jendso/bvad114.1172

Ejemplares similares